X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Stoke intends to use the net proceeds to fund research, clinical and process development and manufacturing of its product candidates, including late-stage development of STK-001, in clinical testing for the treatment of Dravet syndrome and further development of STK-002.
Lead Product(s): Zorevunersen Sodium
Therapeutic Area: Neurology Product Name: STK-001
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $125.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 27, 2024
Details:
Stoke intends to use the net proceeds to fund research, clinical and process development and manufacturing of its product candidates, including late-stage development of STK-001, in clinical testing for the treatment of Dravet syndrome and further development of STK-002.
Lead Product(s): Zorevunersen Sodium
Therapeutic Area: Neurology Product Name: STK-001
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $75.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 26, 2024
Details:
STK-001 (zorevunersen sodium) is a proprietary antisense oligonucleotide (ASO), has the potential to be the first disease-modifying therapy to address the genetic cause of Dravet syndrome.
Lead Product(s): Zorevunersen Sodium
Therapeutic Area: Neurology Product Name: STK-001
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 25, 2024
Details:
STK-001 is designed to upregulate NaV1.1 protein expression by leveraging the non-mutant copy of the SCN1A gene to restore physiological NaV1.1 levels, thereby reducing both occurrence of seizures and significant non-seizure comorbidities related to dravet syndrome.
Lead Product(s): STK-001
Therapeutic Area: Neurology Product Name: STK-001
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 25, 2023
Details:
STK-002 is a proprietary antisense oligonucleotide,designed to restore OPA1 protein expression by upregulating protein production from the non-mutant, wild-type, copy of OPA1 gene, thus slowing or even stopping vision loss in patients with autosomal dominant optic atrophy.
Lead Product(s): STK-002
Therapeutic Area: Genetic Disease Product Name: STK-002
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 25, 2023
Details:
STK-001 is designed to upregulate NaV1.1 protein expression by leveraging the non-mutant copy of the SCN1A gene to restore physiological NaV1.1 levels, thereby reducing both occurrence of seizures and significant non-seizure comorbidities related to dravet syndrome.
Lead Product(s): STK-001
Therapeutic Area: Neurology Product Name: STK-001
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 15, 2023
Details:
STK-001 is an investigational new medicine for the treatment of Dravet syndrome. Stoke believes that STK-001, a proprietary antisense oligonucleotide (ASO), has the potential to be the first disease-modifying therapy to address the genetic cause of Dravet syndrome.
Lead Product(s): STK-001
Therapeutic Area: Neurology Product Name: STK-001
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 02, 2022
Details:
Data presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting will support the Company’s work to advance STK-002 as the first potential disease modifying treatment for Autosomal Dominant Optic Atrophy.
Lead Product(s): STK-002
Therapeutic Area: Genetic Disease Product Name: STK-002
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 02, 2022
Details:
STK-002 is a proprietary antisense oligonucleotide, designed to upregulate OPA1 protein expression by leveraging non-mutant copy of OPA1 gene to restore OPA1 protein expression with aim to stop or reverse vision loss in patients with ADOA.
Lead Product(s): STK-002
Therapeutic Area: Genetic Disease Product Name: STK-002
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 07, 2022
Details:
Collaboration of two companies involves to discover, develop and commercialize RNA-based medicines for potential treatment of rare genetic neurodevelopmental diseases, SYNGAP1 syndrome, Rett syndrome, and undisclosed neurodevelopmental target of mutual interest.
Lead Product(s): RNA-based Therapy
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Acadia Pharmaceuticals
Deal Size: $967.0 million Upfront Cash: $60.0 million
Deal Type: Collaboration January 10, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
